Lentiviral gene delivery to CNS by spinal intrathecal administration to neonatal mice

被引:20
作者
Fedorova, E
Battini, L
Prakash-Cheng, A
Marras, D
Gusella, GL
机构
[1] CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA
关键词
lentiviral vectors; gene therapy; spinal injections; secreted alkaline phosphatase; beta-galactosidase; central nervous system;
D O I
10.1002/jgm.861
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background Direct injection of lentivectors into the central nervous system (CNS) mostly results in localized parenchymal transgene expression. Intrathecal gene delivery into the spinal canal may produce a wider dissemination of the transgene and allow diffusion of secreted transgenic proteins throughout the cerebrospinal fluid (CSF). Herein, we analyze the distribution and expression of LacZ and SEAP transgenes following the intrathecal delivery of lentivectors into the spinal canal. Methods Four weeks after intrathecal injection into the spinal canal of newborn mice, the expression of the LacZ gene was assessed by histochemical staining and by in situ polymer chain reaction (PCR). Following the spinal infusion of a lentivector carrying the SEAP gene, levels of enzymatically active SEAP were measured in the CSF, blood serum, and in brain extracts. Results Intrathecal spinal canal delivery of lentivectors to newborn mice resulted in patchy, widely scattered areas of beta-gal expression mostly in the meninges. The transduction of the meningeal cells was confirmed by in situ PCR. Following the spinal infusion of a lentivector carrying the SEAP gene, sustained presence of the reporter protein was detected in the CSF, as well as in blood serum, and brain extracts. Conclusions These findings indicate that intrathecal injections of lentivectors can provide significant levels of transgene expression in the meninges. Unlike intracerebral injections of lentivectors, intrathecal gene delivery through the spinal canal appears to produce a wider diffusion of the transgene. This approach is less invasive and may be useful to address those neurological diseases that benefit from the ectopic expression of soluble factors impermeable to the blood-brain barrier. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:414 / 424
页数:11
相关论文
共 55 条
[1]   Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding bcl-2 [J].
Azzouz, M ;
Hottinger, A ;
Paterna, JC ;
Zurn, AD ;
Aebischer, P ;
Büeler, H .
HUMAN MOLECULAR GENETICS, 2000, 9 (05) :803-811
[2]   Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain [J].
Baekelandt, V ;
Eggermont, K ;
Michiels, M ;
Nuttin, B ;
Debyser, Z .
GENE THERAPY, 2003, 10 (23) :1933-1940
[3]   Gene therapy in autoimmune, demyelinating disease of the central nervous system [J].
Baker, D ;
Hankey, DJR .
GENE THERAPY, 2003, 10 (10) :844-853
[4]   Lentiviral vectors as a gene delivery system in the mouse midbrain:: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF [J].
Bensadoun, JC ;
Déglon, N ;
Tseng, JL ;
Ridet, JL ;
Zurn, AD ;
Aebischer, P .
EXPERIMENTAL NEUROLOGY, 2000, 164 (01) :15-24
[5]  
Blomer U, 1997, J VIROL, V71, P6641
[6]   Bcl-xL protects adult septal cholinergic neurons from axotomized cell death [J].
Blömer, U ;
Kafri, T ;
Randolph-Moore, L ;
Verma, IM ;
Gage, FH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (05) :2603-2608
[7]   Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-α soluble receptor I variants [J].
Bloquel, C ;
Bessis, N ;
Boissier, MC ;
Scherman, D ;
Bigey, P .
HUMAN GENE THERAPY, 2004, 15 (02) :189-201
[8]   Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer [J].
Bosch, A ;
Perret, E ;
Desmaris, N ;
Trono, D ;
Heard, JM .
HUMAN GENE THERAPY, 2000, 11 (08) :1139-1150
[9]   Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector [J].
Cara, A ;
Rybak, SM ;
Newton, DL ;
Crowley, R ;
Rottschafer, SE ;
Reitz, MS ;
Gusella, GL .
GENE THERAPY, 1998, 5 (01) :65-75
[10]   Gene therapy progress and prospects: gene therapy of lysosomal storage disorders [J].
Cheng, SH ;
Smith, AE .
GENE THERAPY, 2003, 10 (16) :1275-1281